MedTrace Logo

Autologous BMMNC Combined With HA Therapy for PAOD

NCT03214887 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2022-03-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of hyaluronan combined with autologous bone marrow mononuclear cells for the treatment of critical PAOD patients.

Conditions

  • Peripheral Arterial Occlusive Disease
  • Critical Limb Ischemia

Interventions

BIOLOGICAL

RV-P1501

Gel-like product with BMMNCs in each ml of hyaluronan (HA) solution

Sponsors & Collaborators

  • National Taiwan University Hospital

    collaborator OTHER

  • National Cheng-Kung University Hospital

    collaborator OTHER

  • Academia Sinica, Taiwan

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-17
Primary Completion
2018-06-30
Completion
2018-07-27

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03214887 on ClinicalTrials.gov